Skip to main content
Search

Aignostics

2 related articles

Subscribe to updates
  1. Aignostics

    HETA widens spatial H&E readouts to immune phenotyping and mitosis, ranking lymphocyte density in tumor core and margin against a pan-cancer TCGA reference

    Aignostics updated HETA, its spatial H&E analysis platform, adding immune phenotyping readouts, tumor-infiltrating lymphocyte analysis, mitosis detection, and nerve and fat segmentation. Immune phenotyping measures lymphocyte density in the tumor core and at its margins separately, each ranked against a pan-cancer TCGA reference, as continuous values rather than one label per slide, so researchers can set their own inflamed, excluded and desert thresholds. The platform also outputs counts and densities of mature and immature tertiary lymphoid structures and extends tissue segmentation to 9 classes, as the basis for future perineural invasion readouts.

  2. Aignostics

    Aignostics launches HETA Clinical pathology AI family: measure tumor content before molecular testing

    Aignostics released HETA Clinical, a family of pan-cancer AI products spanning the pathology workflow, with four initial products measuring slide quality, tumor presence, mitotic counts and tumor cellularity. These assessments are usually made by eye, which is time-consuming and varies between readers; pathologists the company spoke with at academic medical centers and precision medicine labs estimate that 10 to 20 percent of molecular tests fail because tissue lacks enough tumor. Built on the HETA platform, the products are positioned to confirm sufficient tumor before molecular testing and help labs prioritize cases.

You’re all caught up